Vasopressin versus noradrenaline as initial therapy in septic shock. Is vasopressin-related renal protection doomed to “vanish” in the haze?

Patrick M. Honore, Rita Jacobs, Elisabeth De Waele, Inne Hendrickx, Herbert D. Spapen

Abstract

Gordon et al. recently reported the results of the multicenter Vasopressin vs. Norepinephrine as Initial Therapy in Septic Shock (VANISH) trial comparing the effect of these two potent vasopressors on kidney failure in adult patients with septic shock (1).